BDX BECTON DICKINSON & CO
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 10795 · Fiscal year ends 09/30
Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.2%
TTM net income YoY-40.6%
TTM EPS YoY-39.5%
Revenue 3-yr CAGR3.0%
Net income 3-yr CAGR-17.3%
Margins
Gross margin46.4%
Operating margin9.6%
Net margin4.5%
FCF margin13.1%
EBITDA margin21.6%
Returns
ROE3.8%
ROA1.8%
ROIC (approx.)4.2%
Asset turnover0.39x
Leverage & solvency
Liabilities / assets51.9%
Debt / equity0.69x
Current ratio0.87x
Interest coverage3.40x
Cash quality & payout
Operating cash flow / net income3.67x
Accruals ratio-4.8%
Payout ratio124.5%
Capex / revenue3.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-06-30 | 2026Q22026-03-31 | 2026Q12025-12-31 | 2025Q4*2025-09-30 | 2025Q32025-06-30 | 2025Q22025-03-31 | 2025Q12024-12-31 | 2024Q4*2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $4.98B | $4.71B | $5.25B | $5.89B | $4.73B | $4.48B | $5.17B | $5.44B |
| Cost of revenue | $2.67B | $2.56B | $2.84B | $3.09B | $2.49B | $2.62B | $2.93B | $2.95B |
| Gross profit | $2.31B | $2.15B | $2.41B | $2.80B | $2.23B | $1.86B | $2.23B | $2.49B |
| R&D expense | $258.00M | $249.00M | $306.00M | $322.00M | $230.00M | $232.00M | $343.00M | $302.00M |
| SG&A expense | $1.26B | $1.21B | $1.39B | $1.37B | $1.16B | $1.12B | $1.32B | $1.26B |
| Operating income | $663.00M | $93.00M | $552.00M | $697.00M | $739.00M | $383.00M | $453.00M | $622.00M |
| Interest expense | $132.00M | $149.00M | $153.00M | $155.00M | $152.00M | $150.00M | $155.00M | $155.00M |
| Pretax income | $554.00M | $39.00M | $393.00M | $975.00M | $569.00M | $201.00M | $306.00M | $514.00M |
| Income tax | $102.00M | $76.00M | $11.00M | $17.00M | $118.00M | $43.00M | $3.00M | $114.00M |
| Net income | $377.00M | -$311.00M | $382.00M | $493.00M | $574.00M | $308.00M | $303.00M | $400.00M |
| EBITDA | $1.23B | $656.00M | $1.17B | $1.45B | $1.31B | $950.00M | $1.06B | $1.21B |
| EPS (basic) | 1.37 | -1.11 | 1.34 | — | 2.00 | 1.07 | 1.05 | — |
| EPS (diluted) | 1.37 | -1.11 | 1.34 | — | 2.00 | 1.07 | 1.04 | — |
| Dividends declared per share | 1.05 | 1.05 | 1.05 | 1.04 | 1.04 | 1.04 | 1.04 | 0.95 |
| Weighted avg. shares (diluted) | 275.16M | 280.64M | 285.85M | — | 287.22M | 287.74M | 290.39M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $708.00M | $813.00M | $740.00M | $567.00M | $727.00M | $681.00M | $813.00M | $1.79B |
| Receivables | $2.36B | $2.21B | $2.51B | $2.40B | $2.94B | $3.03B | $2.64B | $3.03B |
| Inventory | $3.32B | $3.36B | $4.08B | $3.15B | $3.95B | $3.72B | $3.86B | $3.84B |
| Current assets | $8.14B | $8.01B | $9.19B | $9.26B | $9.00B | $8.67B | $8.66B | $10.47B |
| PP&E, net | $6.08B | $6.08B | $6.97B | $6.38B | $6.82B | $6.65B | $6.60B | $6.82B |
| Goodwill | $25.94B | $25.95B | $26.62B | $25.96B | $26.60B | $26.44B | $26.33B | $26.46B |
| Intangibles | $8.02B | $8.35B | $9.01B | $9.23B | $9.77B | $10.12B | $10.47B | $10.87B |
| Total assets | $50.73B | $50.83B | $54.84B | $55.33B | $54.90B | $54.47B | $54.66B | $57.29B |
| Current liabilities | $9.40B | $8.51B | $8.76B | $8.31B | $8.16B | $7.69B | $7.66B | $8.96B |
| Short-term debt | $3.30B | $2.57B | $2.62B | $1.56B | $1.81B | $1.60B | $1.32B | $2.17B |
| Long-term debt | $13.51B | $14.71B | $16.92B | $17.62B | $17.53B | $17.67B | $17.44B | $17.94B |
| Total debt | $16.81B | $17.28B | $19.54B | $19.18B | $19.34B | $19.27B | $18.76B | $20.11B |
| Total liabilities | $26.32B | $26.70B | $29.56B | $29.93B | $29.43B | $29.23B | $29.46B | $31.40B |
| Shareholders' equity | $24.42B | $24.13B | $25.28B | $25.39B | $25.47B | $25.24B | $25.20B | $25.89B |
| Net debt | $16.10B | $16.47B | $18.80B | $18.61B | $18.61B | $18.59B | $17.95B | $18.32B |
| Cash flow statement | ||||||||
| Operating cash flow | $776.00M | $671.00M | $657.00M | $1.35B | $1.09B | $164.00M | $693.00M | $1.18B |
| Capital expenditure | $143.00M | $125.00M | $108.00M | $352.00M | $164.00M | $129.00M | $105.00M | $296.00M |
| Free cash flow | $633.00M | $546.00M | $549.00M | $1.00B | $925.00M | $35.00M | $588.00M | $882.00M |
| Investing cash flow | -$241.00M | -$139.00M | -$183.00M | -$494.00M | -$300.00M | -$192.00M | $204.00M | -$3.94B |
| Financing cash flow | -$577.00M | -$414.00M | -$302.00M | -$809.00M | -$841.00M | -$39.00M | -$1.93B | $124.00M |
| Depreciation & amortization | $564.00M | $563.00M | $614.00M | $756.00M | $575.00M | $567.00M | $607.00M | $586.00M |
| Stock-based compensation | $55.00M | $58.00M | $91.00M | $79.00M | $48.00M | $59.00M | $90.00M | $51.00M |
| Dividends paid | $286.00M | $290.00M | $299.00M | $297.00M | $299.00M | $298.00M | $302.00M | $275.00M |
| Share buybacks | $0 | $2.00B | $250.00M | $250.00M | $0 | $0 | $750.00M | $0 |
Free plan shows the latest 8 periods; Pro shows all 73 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.